A5101924594- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Advanced Biosensing Techniques and Applications
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Cell Image Analysis Techniques
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Bone health and treatments
- Higher Education and Teaching Methods
- PI3K/AKT/mTOR signaling in cancer
- Esophageal Cancer Research and Treatment
- Biosimilars and Bioanalytical Methods
- Estrogen and related hormone effects
Fudan University Shanghai Cancer Center
2011-2025
Shanghai Medical College of Fudan University
2010-2023
Fudan University
2009-2022
Kelun Group (China)
2022
Shanghai University
2022
Sun Yat-sen University
2021
Sun Yat-sen University Cancer Center
2021
Shanghai Cancer Institute
2007-2021
Chinese PLA General Hospital
2021
National University of Defense Technology
2019
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of inhibitor capivasertib, as an addition to fulvestrant therapy, patients with hormone receptor-positive advanced breast cancer are limited.
Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy of pyrotinib versus lapatinib, both combination with capecitabine, women human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer open-label, multicenter, randomized II study.Chinese patients HER2-positive relapsed or previously treated taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400...
As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) for recurrent or metastatic NPC (RM-NPC) refractory standard chemotherapy.In this single-arm, multicenter phase II study, patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression unacceptable toxicity. The...
LBA1000 Background: T-DXd is approved for HER2-low (IHC 1+ or 2+/ISH-negative) mBC after ≥1 line of chemotherapy (CT). DB-06 (NCT04494425) evaluated in pts with -ultralow 0 membrane staining), HR+ disease progression (PD) on endocrine-based therapy and no prior CT mBC. Methods: Pts -ultralow, were randomized 1:1 to 5.4 mg/kg TPC. had mBC, ≥2 lines ET 1 if PD occurred ≤24 months (mo) adjuvant ≤6 mo ET+CDK4/6i Primary endpoint was progression-free survival (PFS) by blinded independent central...
Background: Pyrotinib is an irreversible pan-ErbB inhibitor targeting epidermal growth factor receptor, human receptor 2 (HER2), and HER4. This randomized, double-blinded phase 3 study evaluated the efficacy safety of pyrotinib plus capecitabine for HER2-positive local relapsed or metastatic breast cancer. Methods: Patients who had been treated with trastuzumab taxanes were randomized (2:1) to receive either oral placebo (400 mg, qd) (1,000 mg/m2, bid on days 1–14) 21-day cycles, using...
In this phase I study, the safety, pharmacokinetics, and antitumour activity of HER2-targeted antibody-drug conjugate A166 were evaluated in patients with HER2-expressing advanced solid tumours. Patients tumours refractory to standard therapies received at doses 0.1, 0.3, 0.6, 1.2, 2.4, 3.6, 4.8 or 6.0 mg/kg Q3W a "3 + 3" design. Dose cohorts expanded Q3W. Primary endpoints assessment safety tolerability identification maximum tolerated dose recommended II dose. total, 81 enroled (n = 1 for...
Abstract Background: AKT pathway activation has been implicated in the development of endocrine therapy resistance hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) advanced breast cancer (ABC). In Phase II, placebo (PBO)-controlled FAKTION trial, addition pan-AKT inhibitor capivasertib to fulvestrant significantly improved progression-free survival (PFS) and overall postmenopausal women with aromatase (AI)-resistant HR+/HER2– ABC. The III, randomized,...
High level of serum lactate dehydrogenase (LDH) is a well-known poor prognostic factor in patients with malignancies. However, there was no data on overall survival (OS) cancer LDH > 1000 IU/L, and the value changes over time for OS had not been reported. Clinical 311 metastatic disease >1000 IU/L (four times upper limit normal) admitted consecutively to single center were reviewed this retrospective study. ranged from 1002 8235 U/L mean 1689 U/L. The median 1.7 months (95 % CI: 1.4-2.0)....
KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. This first-in-human phase I study evaluated the safety/tolerability, pharmacokinetics, preliminary efficacy, and potential predictive biomarker activity of administered as monotherapy patients with HER2-positive metastatic breast cancer (MBC).Female MBC who had progressed on prior anti therapies received intravenous at 5 mg/kg (once weekly), 10 20 every 2 weeks), or 30 3 weeks). Dose escalation was...
Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocrine therapy. Patients were randomized (2:1) to oral 25 mg/day (n = 235) or placebo 119) 5 mg/week 28-day cycles. The primary endpoint was independent radiographic committee (IRC)-assessed progression-free survival...
Abstract Chronic liver diseases usually developed through stepwise pathological transitions under the persistent risk factors. The molecular changes during are pivotal to improve diagnostics and therapeutics yet still remain elusive. Cumulative large-scale transcriptomic studies have been revealing landscape of various conditions at bulk single-cell resolution, however, neither single experiment nor databases enabled thorough investigations dynamics along progression diseases. Here we...
Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess equivalence LY01011 denosumab terms efficacy and safety. Eligible BM from solid tumors were randomized at 1:1 ratio receive 120 mg or subcutaneously every four weeks during 12-week double-blind period, then all enrolled continued until week 53. The primary endpoint natural logarithm change urinary N-terminal crosslinked...
Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor 2 (HER2)-positive breast cancer (BC), focusing on efficacy lapatinib-treated patients and brain metastasis.One hundred thirteen with HER2-positive BC treated Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 2019 were included.Over...
HLX02 is an approved biosimilar of trastuzumab. This study aimed to evaluated the efficacy, safety, and immunogenicity compared with reference trastuzumab in patients human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer. randomized, double-blind, phase III was conducted at 89 centers China, Philippines, Poland, Ukraine. Eligible were randomized (1:1) receive European Union (EU)-sourced (initial dose 8 mg/kg, followed by 6 mg/kg every 3 weeks for up...
Breast cancer is now the most common malignant tumor worldwide. About one-fourth of female patients all over world suffer from breast cancer. And about one in six deaths worldwide caused by In terms absolute numbers cases and deaths, China ranks first world. The CACA Guidelines for Holistic Integrative Management Cancer were edited to help improve diagnosis comprehensive treatment China.
1003 Background: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine showed clinically meaningful benefits and acceptable tolerability in patients (pts) with HER2+ metastatic breast cancer (MBC) phase 1 2 studies. Methods: This open-label, multicenter, randomized 3 study enrolled MBC pts after trastuzumab taxanes, and/or anthracyclines. Up to two prior lines of chemotherapy (chemo) for disease were allowed. Pts randomly assigned (1:1) receive pyrotinib 400 mg or lapatinib 1250...
The LORDSHIPS study aimed to explore the safety and efficacy of a novel fully oral triplet combination dalpiciclib (a potent cyclin-dependent kinase 4/6 inhibitor), pyrotinib HER2 tyrosine inhibitor) endocrine therapy letrozole in patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) front-line setting.Postmenopausal women HR-positive MBC were recruited dose-finding phase Ib trial. A standard 3 + design was used determine safety, tolerability, recommended...
Abstract Background Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer and primary resistance to trastuzumab have a poor clinical outcome lack good evidence inform decision. This study investigated the efficacy safety of pyrotinib plus capecitabine in this population. Methods phase trial was conducted at 16 sites China. received oral 400 mg once daily 1000 mg/m twice day on days 1–14 each 21-day cycle until disease progression or intolerable...